RGD Reference Report - Induction of secretory leukocyte protease inhibitor (SLPI) in estradiol valerate (EV) induced polycystic ovary. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Induction of secretory leukocyte protease inhibitor (SLPI) in estradiol valerate (EV) induced polycystic ovary.

Authors: Park, JJ  Bae, CS  Choi, BD  Jeong, SJ  Wang, G  Lim, DS  Kim, BO  Cho, YS  Kim, SJ  Jeong, MJ 
Citation: Park JJ, etal., Arch Pharm Res. 2011 Aug;34(8):1389-97. doi: 10.1007/s12272-011-0820-x. Epub 2011 Sep 11.
RGD ID: 9999396
Pubmed: PMID:21910062   (View Abstract at PubMed)
DOI: DOI:10.1007/s12272-011-0820-x   (Journal Full-text)

The excessive administration of estradiol valerate induces polycystic ovary syndrome by formation of follicular cysts. Secretory leukocyte protease inhibitor (SLPI) promotes wound healing by decreasing the excessive inflammatory response, stimulating keratinocyte proliferation and increasing collagen deposition through the inhibition of protease activity. In this study, SLPI expression was high in the ovarian stroma, corpus luteum, unilaminar primary follicle, multilaminar primary follicle and granulose layer of the antral follicle in polycystic ovary (PCO) compared to the normal ovary. SLPI was expressed strongly in the theca around the cyst in PCO compared to the mature follicle in the normal ovary. The levels of SLPI mRNA and protein expression were higher in PCO than in the normal ovary, and the level of MMP-2 expression was lower in PCO. These results showed that the formation of a cyst was initiated from a multilaminar primary follicle and SLPI expression was increased depending on the morphological changes in the follicle and ovarian stroma. Therefore, an increase in SLPI may be related to the suppression of tissue disruption, and act as a protease inhibitor in PCO, suggesting that SLPI increases independently of the estrogen concentration in pathological tissues.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
MMP2Humanpolycystic ovary syndrome  ISOMmp2 (Rattus norvegicus)protein:decreased expression:ovaryRGD 
Mmp2Ratpolycystic ovary syndrome  IEP protein:decreased expression:ovaryRGD 
Mmp2Mousepolycystic ovary syndrome  ISOMmp2 (Rattus norvegicus)protein:decreased expression:ovaryRGD 
SLPIHumanpolycystic ovary syndrome  ISOSlpi (Rattus norvegicus)protein:increased expression:ovaryRGD 
SlpiRatpolycystic ovary syndrome  IEP protein:increased expression:ovaryRGD 
SlpiMousepolycystic ovary syndrome  ISOSlpi (Rattus norvegicus)protein:increased expression:ovaryRGD 

Objects Annotated

Genes (Rattus norvegicus)
Mmp2  (matrix metallopeptidase 2)
Slpi  (secretory leukocyte peptidase inhibitor)

Genes (Mus musculus)
Mmp2  (matrix metallopeptidase 2)
Slpi  (secretory leukocyte peptidase inhibitor)

Genes (Homo sapiens)
MMP2  (matrix metallopeptidase 2)
SLPI  (secretory leukocyte peptidase inhibitor)


Additional Information